中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.008 seconds)

    TREATMENT OF DISEASE
    1.
    发明申请
    TREATMENT OF DISEASE 审中-公开
    治疗疾病

    公开(公告)号：WO2008065386A1

    公开(公告)日：2008-06-05

    申请号：PCT/GB2007/004536

    申请日：2007-11-27

    Applicant: DIURNAL LIMITED ,  ROSS, Richard

    Inventor： ROSS, Richard

    IPC: A61K31/57 ,  A61K9/28 ,  A61P25/24

    CPC classification number: A61K31/57

    Abstract: We describe a medicament for the treatment of diseases or conditions that are typically treatable with steroids, in particular glucocorticoids, wherein the treatment with the steroid results in the suppression of the endogenous adrenal gland circadian secretion of Cortisol.

    Abstract translation: 我们描述了用于治疗通常可用类固醇，特别是糖皮质激素治疗的疾病或病症的药物，其中用类固醇治疗导致抑制皮质醇的内源性肾上腺昼夜分泌。

    HYDROCORTISONE CONTROLLED RELEASE FORMULATION
    5.
    发明申请
    HYDROCORTISONE CONTROLLED RELEASE FORMULATION 审中-公开
    盐酸盐控制释放配方

    公开(公告)号：WO2013121184A1

    公开(公告)日：2013-08-22

    申请号：PCT/GB2013/050311

    申请日：2013-02-12

    Applicant: DIURNAL LIMITED

    Inventor： HUATAN, Hiep ,  ROSS, Richard ,  WHITAKER, Martin

    IPC: A61K9/50 ,  A61K31/573

    CPC classification number: A61K9/5026 ,  A61K9/5078 ,  A61K31/573

    Abstract: The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.

    Abstract translation: 本公开涉及包含氢化可的松的药物制剂及其用于治疗可受益于氢化可的松的延迟释放，特别是诸如肾上腺功能不全，炎性病症和抑郁症的病症的病症。

    TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION
    6.
    发明申请
    TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION 审中-公开

    公开(公告)号：WO2021156043A1

    公开(公告)日：2021-08-12

    申请号：PCT/EP2021/050930

    申请日：2021-01-18

    Applicant: DIURNAL LIMITED

    Inventor： WHITAKER, Martin ,  PORTER, John ,  ROSS, Richard ,  JONES, Stewart ,  COCKS, Elizabeth

    IPC: A61K31/568 ,  A61K47/44 ,  A61K47/10 ,  A61K47/14 ,  A61P5/26 ,  A61K9/00 ,  A61K9/48

    Abstract: A pharmaceutical composition for adapted for oral administration comprising at least 10 % w/w native testosterone, at least 36% w/w sesame oil, at least 28% w/w propylene glycol monolaurate, at least 9 % w/w ethanol and at least 14 % w/w benzyl alcohol. A dosage regimen for use in a human subject comprising administering at least a first and a second pharmaceutical compositions wherein, the first composition comprises between 2.5-7.5 % w/w native testosterone, sesame oil, propylene glycol monolaurate, ethanol and benzyl alcohol; and the second composition comprises at least 9% w/w native testosterone, sesame oil, propylene glycol monolaurate, ethanol and benzyl alcohol; wherein said first and second compositions are administered orally at least once in a 24- hour period to said human subject to normalise serum testosterone. A process to produce a composition comprising native testosterone comprising i) forming a homogeneous preparation comprising sesame oil, propylene glycol monolaurate, benzyl alcohol and ethanol; ii) adding native testosterone at a concentration of about 13% w/w to said homogeneous preparation to form a combined testosterone preparation; and iii) mixing the combined preparation to dissolve testosterone to form a substantially clear preparation.

Patent Agency Ranking